More effective treatments urgently needed for adolescent depression

Public release date: 7-Mar-2012 [ | E-mail | Share ]

Contact: Cathia Falvey cfalvey@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, Mar 07, 2012--More than 2 million teenagers suffer from depression in the U.S. Recent drug warnings and study results have led to increased controversy surrounding the treatment of adolescent depression. A state-of-the-art issue reporting on the latest research findings on antidepressant medications combined with appropriate therapeutic strategies has been published by Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc. The special issue on psychopharmacology of adolescent depression is available free on the Journal of Child and Adolescent Psychopharmacology website.

"There are no radically new treatments on the horizon for the treatment of depression, and so we have to do better with the treatments we have available," says Graham J. Emslie, MD, Guest Editor of the issue and Director of Child Psychiatry at University of Texas Southwestern Medical Center, Dallas. "Few youths with depression receive adequate treatment."

The issue focuses on the controversy, the data, and the challenges and opportunities in the care of adolescents with major depressive illness. The articles cover a wide range of issues that all contribute to the goal of improving outcomes. Included in the issue, Greg Clarke, PhD et al., Kaiser Permanente Center for Health Research (Portland, OR), present an evaluation of new and refill antidepressant prescribing practices among physicians before and after warnings related to teen suicide risk were issued. Kenneth Wells, MD, MPH and colleagues from University of California, Los Angeles, and Stony Brook University (NY), explore the effectiveness of appropriate care delivered in a primary care setting. Dr. Emslie and colleagues from UT Southwestern Medical Center examine the common problem of insomnia in youths with depression and its impact on treatment.

"Depression is a major public health concern among young people, particularly teens, but many people have a hard time talking about it," says Harold S. Koplewicz, MD, Editor-in-Chief of Journal of Child and Adolescent Psychopharmacology, and President, Child Mind Institute, New York, NY. "Advancing research is one way we can work to change a culture of denial that too often stands in the way of effective and sometimes life-saving treatment."

###

About the Journal

Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published bimonthly in print and online. The journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed online at the Journal of Child and Adolescent Psychopharmacology website.

About the Company

View post:
More effective treatments urgently needed for adolescent depression

From ‘Refrigerator Mothers’ to untangling the genetic roots of autism

Public release date: 7-Mar-2012 [ | E-mail | Share ]

Contact: Michael Bernstein m_bernstein@acs.org 202-872-6042 American Chemical Society

With the "Refrigerator Mother" notion about the cause of autism a distant and discredited memory, scientists are making remarkable progress in untangling the genetic roots of the condition, which affects millions of children and adults, according to an article in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

In the story, C&EN Associate Editor Lauren K. Wolf points out that most people in the 1960s believed autism resulted from a lack of maternal warmth and emotional attachment. It was a hypothesis popularized by Austrian-born American child psychologist and writer Bruno Bettelheim. Now scientists around the globe are focusing on genes that have been implicated in autism and related conditions, collectively termed "autism spectrum disorders." That research may solve mysteries about autism, which affects 1 in 110 children in the U.S. Among them: what causes autism, why does it affect more boys than girls and what can be done to prevent and treat it?

C&EN explains that scientists now have solidly implicated certain genes as being involved in autism. Most of those genes play a role in the transmission of signals through the junctions or "synapses" between nerve cells. Synapses are the territory where one nerve releases a chemical signal that hands off messages to an adjoining nerve. The human brain has an estimated 1,000 trillion synapses, and they are hot spots for miscommunications that underpin neurological disorders like autism. Scientists now are gleaning information on what those genes do, what brain circuits they affect and how the proteins they produce function. In doing so, they are paving the way for future medications for autism spectrum disorders.

###

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society contact newsroom@acs.org.

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Go here to read the rest:
From 'Refrigerator Mothers' to untangling the genetic roots of autism

DNA Altered By Strenuous Exercise And A Strong Cup Of Coffee

March 7, 2012

Bad news for those who use their genetic makeup as an excuse not to hit the gym: Researchers have found that our DNA can be altered with just a few minutes of strenuous exercise.

Writing in the March issue of Cell Press publication Cell Metabolism, researchers have posted results of a study which prove that strenuous exercise, even as brief as a minute, can immediately change our DNA.

By studying healthy yet inactive men and women, these researchers found that we are more in control of our bodies than we have previously thought.

The changes made to the DNA molecules isnt a complete overhaul, however. The basic genetic code that makes up the DNA remains the same. What modifications are made appear to be the early stages of genetic reprogramming. This reprogramming is the foundation for building muscle strength and ultimately the metabolic benefits of exercise.

In other words, exercise jump starts your DNA to begin to burn fat and build muscle. According to the Cell Metabolism report, even a brief yet brisk 20 minute bicycle ride can make all the difference.

Researcher Juleen Zierath of the Karolinska Institute of Sweden had this to say about their findings: Our muscles are really plastic. We often say that you are what you eat. Well, muscle adapts to what you do. If you dont use it, you lose it and this is one of the mechanisms that allows this to happen.

Along with colleagues from Dublin and Denmark, Professor Zierath conducted 2 experiments with men who did not exercise regularly, yet were relatively healthy. The researchers had the men exercise vigorously on an exercise bike before they took slivers of muscle from the mens thighs. The DNA found in these muscle tissue samples were then analyzed for chemical changes.

A simple walk in the park may not be enough to spark this genetic change, however. According to the research, a person must be out of breath and, while able to speak, must have some difficulty carrying on a conversation.

The results of these tests showed similar results from contracted muscle tissues created in a test-tube from previous research. The muscle tissue also reacted similarly when subjected to the caffeine.

Go here to read the rest:
DNA Altered By Strenuous Exercise And A Strong Cup Of Coffee

Posted in DNA

DNA study: Gorillas even more similar to us than we thought

LOS ANGELES - Take a trip to the zoo and you can see gorillas are a lot like us. But a new DNA study says we're even more similar than scientists thought.

From the evolutionary family tree, you'd expect our DNA to be the most similar to chimps, our closest relatives. The new work found that's true for the most part, but it also found that a sizable portion of our genome is closer to a gorilla's than to a chimp's.

"The chimpanzee is often cited as 'our closest living relative,' and this is certainly true based on total genome sequence, but the gorilla is nearly as close a relative," Owen Lovejoy of Kent State University, who was not part of the project, said in an email.

That agrees with hints from with some smaller previous

This undated image provided by San Diego Zoo Global shows a female western lowland gorilla named Kamilah at the San Diego Zoo Safari Park in San Diego, Calif. Scientists recently published a draft of her DNA and compared it to the genetic blueprints of humans and chimpanzees to better understand how humans evolved. (AP Photo/San Diego Zoo Global)

It reveals "a closer connection between our genome and that of the gorilla than was previously appreciated," Richard Gibbs and Jeffrey Rogers of the Baylor College of Medicine wrote in an editorial accompanying the work published in today's issue of the journal Nature.

With the new research, scientists now have complete genetic blueprints of the living great apes - humans, chimps, gorillas and orangutans - to compare and gain fresh understanding of how humans evolved and developed such key traits as higher brain function and the ability to walk upright.

Humans and chimps evolved separately since splitting

The latest study was led by scientists at the Wellcome Trust Sanger Institute, a nonprofit British genome research center. Researchers mapped the DNA of a female gorilla and compared it with the genomes of humans and chimps.

As expected, most of the human genome was closer to the chimp's than to the gorilla's. But in about 15 percent of the genome, human and gorilla resemble each other the most. In another 15 percent, chimp and gorilla DNA are closer to each other than chimp is to human.

See more here:
DNA study: Gorillas even more similar to us than we thought

Posted in DNA

Rapid DNA analysis system introduced

Published: March. 7, 2012 at 8:37 AM

CHARLOTTESVILLE, Va., March 7 (UPI) -- A rapid DNA analysis system for forensic, homeland security and intelligence community use is being launched by U.S. firms Lockheed Martin and ZyGem Corp.

The system uses advanced microfluidics and ZyGem's proprietary nucleic acid isolation technology to accelerate DNA identification, all integrated into compact laboratory on a single chip that the companies say reduces DNA processing steps.

"With the successful development of our fully integrated cartridge device, this platform now has the potential to transform today's DNA identification process from one that takes a great deal of training, sophisticated equipment and time into a far simpler, more affordable process that can be performed in the lab or field in under 90 minutes," said Joan Bienvenue, Lockheed Martin program manager and chief scientist.

The technology was unveiled during the recent Annual Scientific Meeting of the American Academy of Forensic Sciences and pre-production units will be made available to key customers this summer.

Here is the original post:
Rapid DNA analysis system introduced

Posted in DNA

Nanomanufacturing using DNA origami

ScienceDaily (Mar. 7, 2012) In recent years, scientists have begun to harness DNA's powerful molecular machinery to build artificial structures at the nanoscale using the natural ability of pairs of DNA molecules to assemble into complex structures. Such "DNA origami," first developed at the California Institute of Technology, could provide a means of assembling complex nanostructures such as semiconductor devices, sensors and drug delivery systems, from the bottom up.

While most researchers in the field are working to demonstrate what's possible, scientists at the National Institute of Standards and Technology (NIST) are seeking to determine what's practical.

According to NIST researcher Alex Liddle, it's a lot like building with LEGOs -- some patterns enable the blocks to fit together snugly and stick together strongly and some don't.

"If the technology is actually going to be useful, you have to figure out how well it works," says Liddle. "We have determined what a number of the critical factors are for the specific case of assembling nanostructures using a DNA-origami template and have shown how proper design of the desired nanostructures is essential to achieving good yield, moving, we hope, the technology a step forward."

In DNA origami, researchers lay down a long thread of DNA and attach "staples" composed of complementary strands that bind to make the DNA fold up into various shapes, including rectangles, squares and triangles. The shapes serve as a template onto which nanoscale objects such as nanoparticles and quantum dots can be attached using strings of linker molecules.

The NIST researchers measured how quickly nanoscale structures can be assembled using this technique, how precise the assembly process is, how closely they can be spaced, and the strength of the bonds between the nanoparticles and the DNA origami template.

What they found is that a simple structure, four quantum dots at the corners of a 70-nanometer by 100-nanometer origami rectangle, takes up to 24 hours to self-assemble with an error rate of about 5 percent.

Other patterns that placed three and four dots in a line through the middle of the origami template were increasingly error prone. Sheathing the dots in biomaterials, a necessity for attaching them to the template, increases their effective diameter. A wider effective diameter (about 20 nanometers) limits how closely the dots can be positioned and also increases their tendency to interfere with one another during self-assembly, leading to higher error rates and lower bonding strength. This trend was especially pronounced for the four-dot patterns.

"Overall, we think that this process is good for building structures for biological applications like sensors and drug delivery, but it might be a bit of a stretch when applied to semiconductor device manufacturing -- the distances can't be made small enough and the error rate is just too high," says Liddle.

Share this story on Facebook, Twitter, and Google:

Read the rest here:
Nanomanufacturing using DNA origami

Posted in DNA

Genome study finds some gorilla DNA aping our own

LOS ANGELES (AP) Take a trip to the zoo and you can see gorillas are a lot like us. But a new DNA study says we're even more similar than scientists thought.

From the evolutionary family tree, you'd expect our DNA to be the most similar to chimps, our closest relatives. The new work found that's true for the most part, but it also found that a sizable portion of our genome is closer to a gorilla's than to a chimp's.

"The chimpanzee is often cited as 'our closest living relative' and this is certainly true based on total genome sequence, but the gorilla is nearly as close a relative," Owen Lovejoy of Kent State University, who was not part of the project, said in an email.

That agrees with hints from with some smaller previous genetic studies. The latest work deciphered the entire genome of the gorilla, which Lovejoy called "a substantial achievement."

It reveals "a closer connection between our genome and that of the gorilla than was previously appreciated," Richard Gibbs and Jeffrey Rogers of the Baylor College of Medicine wrote in an editorial accompanying the work published in Thursday's issue of the journal Nature.

With the new research, scientists now have complete genetic blueprints of the living great apes humans, chimps, gorillas and orangutans to compare and gain fresh understanding of how humans evolved and developed key traits such as higher brain function and the ability to walk upright.

Humans and chimps evolved separately since splitting from a common ancestor about 6 million years ago.

The latest study was led by scientists at the Wellcome Trust Sanger Institute, a nonprofit British genome research center. Researchers mapped the DNA of a female gorilla and compared it to the genomes of humans and chimps.

As expected, most of the human genome was closer to the chimp's than to the gorilla's. But in about 15 percent of the genome, human and gorilla resemble each other the most. In another 15 percent, chimp and gorilla DNA are closer to each other than chimp is to human. Both those situations clash with what you'd expect from the evolutionary tree, which says humans and chimps should always be the most similar, the researchers said.

The analysis also found gene variants in gorillas that are harmless to them but are linked to dementia and heart failure in people.

Read the rest here:
Genome study finds some gorilla DNA aping our own

Posted in DNA

DNA may link dead killer to as many as 26 murders

DENVER (Reuters) - Cold-case detectives have positively matched a deceased serial killer's DNA to the decades-old murders of four women in Denver, and they suspect that he may be responsible for as many as 26 unsolved homicides, authorities said on Wednesday.

Vincent Groves, who was convicted of three slayings and died in prison of natural causes in 1996, has now been tied conclusively to the slayings of three other women in 1979 and one more in 1988, Denver District Attorney Mitch Morrissey said in an interview.

"I fully expect we will tie him to at least one, and possibly three or four other unsolved cases" through DNA, Morrissey said.

Morrissey said investigators were examining possible connections between Groves and 26 unsolved murders but may not be able to positively link him to the entire batch of homicides for which he is a suspect.

Groves was sentenced to life in prison in 1990 for two murders he committed while on parole for a 1982 second-degree murder conviction.

The women Groves killed or is suspected of killing ranged from prostitutes and drug addicts to women he knew from church or in business, Morrissey said.

The victims were typically strangled and sexually assaulted before their bodies were dumped in alleys, rural areas or in the mountains west of Denver, the prosecutor said.

The latest cases positively tied to Groves were closed with the help of a U.S. Justice Department grant that paid for Denver police to use DNA analysis in examining some 250 unsolved murders between 1970 and 1984.

Once detectives learned Groves had a terminal illness, they went to interview him in person seeking confessions to any additional murders he had been suspected of committing.

"He would toy with the detectives and admit he knew the victims or that he was the last person to be seen with them but never confessed to the killings," Morrissey said.

See original here:
DNA may link dead killer to as many as 26 murders

Posted in DNA

Local Middle School Students Win Awards at Regional Science Fair

On March 6, eight middle school students from Lexington and Rockbridge County won awards at the Shenandoah Regional Science Fair at James Madison University.

Three eighth graders from Lylburn Downing Middle School - Harrison Branner, Caroline Connelly and Diego Velasquez - all got gold medals in their categories. Branner also received the Naval Science Award for Earth and Planetary Science awarded by the Office of Naval Research for his Hair Hygrometers Experiment. Connelly competed in behavioral and social science with her experiment on The Effect of Emotion on Perception. Velasquez studied depth perception and competed in the Medicine, Health, and Nutrition Science category.

Spencer Hough and Jackson Beacham were each awarded a silver medal in the engineering category. Hough investigated windmill design and Beacham worked with bilge keels.

Toree Baldwin also received a silver medal in Medicine, Health, and Nutrition Science for her project on Fingerprint Genetics.

Katherine Bowles represented LDMS in the very competitive category of physics with a study on Storing Tennis Balls.

Audrey Johnston is the eighth grade science teacher at LDMS who guided all the students through their independent projects. It was the most awards ever for a group of LDMS students.

Two Maury River Middle School students also received awards.

There were also two winners from Maury River Middle School. Jennifer Hildredth won a bronze medal in the Environmental Science category. Kayleigh Addington received a special award from the Virginia Section of the American Water Works Association, which comes with a $200 savings bond for her project in the earth and planetary science category.

Over 100 middle school students from public and private schools were in the competition.

View original post here:
Local Middle School Students Win Awards at Regional Science Fair

Georgia Tech Selects Prometheus Research for Expedition in Computational Behavioral Science

NEW HAVEN, Conn., March 7, 2012 /PRNewswire/ -- Prometheus Research, a leading provider of data management services for behavioral and biomedical research, announced today that it has been selected by the Georgia Institute of Technology to support their $10M National Science Foundation (NSF) "Expeditions in Computing" Award. Prometheus Research will create a web-based data management infrastructure, based on the extensible RexDB platform, to support research associated with the computing grant. The RexDB-based system will allow collaborators to acquire, curate, and access data and files generated by multiple modalities for the measurement and analysis of behavior in children. The application will be HIPPA-/HITECH-compliant and securely available to remote team members.

"This phase of work will meet the immediate needs of acquiring and sharing data generated by social-interaction protocols, as well as provide a platform to reliably manage future data collected fromquestionnaires," said David Voccola, Chief Operating Officer at Prometheus Research.

Prometheus Research's domain expertise in autism and related disorders makes it an ideal partner for the Georgia Tech team.Prometheus has supported or collaborated on some of the largest and most ambitious autism research endeavors in the world, including the Simons Simplex Collection (SSC) and the National Database for Autism Research (NDAR). The tools and processes they've helped develop in the areas of study governance, data collection, data curation, data distribution, and data persistence are now considered best practices for collaborative research, and are already in use at places like the Yale Child Study Center (CT) and the Marcus Autism Center (GA).

"Georgia Tech is working with Prometheus as part of our NSF Expeditions in Computing Award project to develop novel computational modeling and data analysis techniques for capturing and measuring behaviors relevant to diagnosing and treating autism," said James M. Rehg, professor in the Georgia Tech School of Interactive Computing and principal investigator for this project. "Georgia Tech has selected Prometheus to develop a foundational, first-of-its-kind data management system capable of managing the high-bandwidth media assets associated with the research project, such as video and audio, along with more traditional survey and scientific data sets."

About Prometheus Research

Prometheus Research provides data management services and web-native data-management software to biomedical researchers investigating autism and other neurodevelopmental disorders. Its team specializes in designing and building systems capable of accelerating complex interdisciplinary research and of multiplying the value of hard-won research data. Prometheus staff are consummate innovators, and Prometheus technology powers some of the most ambitious and important research endeavors in autism, including the Simons Foundation Autism Research Initiative (SFARI). Many of these innovations also are made available to the open source software community, most notably HTSQL, an instant Web interface for databases, and the Research Exchange Database, RexDB.

For more information go to http://www.prometheusresearch.com or call us at +1 (800) 693-9057. Reach us by e-mail at Lux@PrometheusResearch.com

Continue reading here:
Georgia Tech Selects Prometheus Research for Expedition in Computational Behavioral Science

Jeremy Lin: Anatomy of a Sports Star and Cultural Sensation

When I did a online search of Jeremy Lin this morning, many of the headlines that popped up were pronouncing an end to the so-called "Linsanity" - that would be the media and cultural frenzy set off by the NY Knicks point guard and his outstanding performance.

Lin is the rookie basketball player who allegedly came out of nowhere to help ramp up the Knicks' season. But beyond the team's future, pundits and fans alike have seized on his accomplishments to ask questions about diversity in sports, how Asians and Asian-Americans are represented (or not) in popular culture and more.

Lin may not keep racking up points, but I doubt the media interest in him is going away - another recent headline promised to reveal "What Jeremy Lin can teach us about dating."

Yeesh. Whether you're into sports or not, you've likely caught wind of this story. The folks over at the Illinois Humanities Council certainly have. They've commissioned a number of people - from the arts, media and academia - to write out their thoughts on the cultural swirl around Lin. I'm going to feature some of their posts in this here blog over the next few days.

Of course you're invited to join the conversation as well. You can weigh in below with your reaction. And why not meet up with the IHC crew at Jane Addams Hull-House Museum next Monday evening for the conversation Linsanity: What's Beyond the Hype?

The "Feel-Good" Story in the Racial Frame: Jeremy Lin and the Same Politics of Race, by David Stovall.

Before any type of deep analysis on the recent rise of Jeremy Lin in the National Basketball Association (NBA), its important to state the facts: In 2006 Jeremy Lin was Northern Californias Player of the Year in Basketball at Palo Alto High. His hometown university of Stanford wouldnt offer him a four-year scholarship and instead offered him the opportunity to play basketball as a walk-on. Coach Dawkins former backcourt running mate at Duke (Tommy Amaker) decided to take a chance on Lin at Harvard.

In 2010 he graduated from Harvard with a degree in economics. Fast-forward six years and you have all the makings for a made-for-TV movie. Lin goes undrafted in the first two rounds of the 2010 draft despite numerous inquiries on his ability to play the point-guard position by NBA scouts, his All-Ivy selection and him being in the top three in assists in the country. His hometown team (the Golden State Warriors) takes him as an undrafted free agent, and he makes the roster. He sees limited playing time as a rookie, gets cut, gets picked up by Houston, gets cut, goes to the NBA developmental league, gets picked up by the Knicks on a 10-day, sleeps on his brother's couch for a couple of days, surfs to another teammate's house for a spot on the couch, and leads the Knicks on a 8-0 winning streak in the process. I know whod a thunk it? All of this is great for the ESPN documentary, but its also absent many of the racial realities of the day. Despite the fallacy of a post-racial society, we still try to obfuscate the realities of race. Without question, Lin is a great talent who deserves to be on the court. Simultaneously our oddity addiction in the U.S. could easily make Lin a caricature of himself. With all of the new monikers that roll off the tongue (Linsanity, Linpossible, etc.), we have to grapple with the fact that Lins individual journey takes place in a social, political and economic context.

Part of that context is the fact that the American mainstream media has an extremely limited number of themes in its repetoire: tragedy/disaster, triumph, scandal or oddity. Commentary with any type of critical analysis is relegated to the fringes as we become engulfed by Lins feel-good story of triumph. Never to discount his struggles, but Lin would have been all right without the NBA. An econ degree from Harvard goes a long way.

Excerpt from:
Jeremy Lin: Anatomy of a Sports Star and Cultural Sensation

ANaToMY oF FeAR…EuRoPean STYLe

'BREAK A LEG'

Do you remember this picture? I do and I'm sure you do as well. It has been all down hill from there hasn't it.

If you don't do this or that, terrible, ugly, horrendous, unfathomable things are going to happen and the blood will all be on your hands. Not the bankers, not the politicians, not the central bankers, not the regulators, not the good little austere sheeple.

This is not simply moral hazard. It is financial extortion and we allowed it to start in America. Now it is polluting the rest of of the world.

American capitalism Wall Street style is what it is, this is the monstrosity that is hijacking the world economy.

We have been listening to this dramatic apocalyptic drone for months, years already and now, during the next 24 hours or so, the cacophony of fear will once again rise to an operatic crescendo.

Something tells me the people who vultured up this crappy Greek paper from the European banks and insurance companies during the past year do not fancy themselves as saviours of the world.

The evil hedge fund speculators should be digging in for another healthy round of financial xenophobia and Euro villification.

See the original post:
ANaToMY oF FeAR...EuRoPean STYLe

AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement?

By Turna Ray

The American Medical Association's Current Procedural Terminology Editorial Panel has approved Vermillion's application for a Category 1 CPT code for its OVA1 test.

According to a published summary of the panel's February meeting, the AMA "accepted establishment of code 814XX1 to describe the OVA1 test." The OVA1 test will also be listed in a new appendix for multi-analyte assays with algorithmic analysis, a subset of tests also known as in vitro diagnostic multivariate index assays.

The AMA decided a few months back that it would grant Category 1 codes to MAAAs that its CPT panel has vetted and found to meet a certain set of criteria. In addition to being listed under Category 1 codes, these tests will also be listed in a special section for MAAAs, called Appendix X. MAAAs that the AMA has not reviewed or that have not met coding criteria under Category 1 will only be listed in Appendix X. Tests in this appendix will be referenced by their proprietary names (PGx Reporter 11/9/2011).

At the February meeting, AMA's CPT panel added a new Category I subheading and guidelines in the "pathology and laboratory" section for MAAAs; established codes (ie. 81499X) to describe unlisted MAAAs with algorithmic analyses; established three new MAAA codes for listing in Appendix X; and revised its chemistry guidelines to include instructions for reporting unlisted MAAA codes.

Other than OVA1, the other two MAAAs that will be listed in Appendix X include a qualitative serum test that uses an algorithm to combine the results of two analytes and women's menopausal status into a numeric score, and a "diabetes pre-diagnostic risk screen" that analyzes multiple analytes to give a single risk score correlated with the probability of developing the disease.

The new MAAA codes will be effective Jan. 1, 2013.

According to Vermillion, in order to garner approval from the AMA for a Category 1 code, the company submitted several peer-reviewed publications on OVA1. Furthermore, the company said the fact that the test has been accepted for coverage by other payers, including Medicare contractor Highmark Medicare Services, also helped. "The new CPT code is a critical step in advancing the commercialization of OVA1, as we believe it will help streamline claims processing and accelerate further coverage and adoption by private payers," Vermillion CEO Gail Page said in a statement.

Currently there are three types of CPT codes payors use to process claims: Category I, II, and III. Many sponsors of IVDMIAs are currently using unlisted or miscellaneous codes under Category I to garner reimbursement for performed tests.

For example, Genomic Health's Oncotype DX is reimbursed with a miscellaneous CPT code and Agendia's MammaPrint uses the CPT code 84999 for "an unlisted chemistry procedure." Some MAAA providers claim to have good reimbursement through this process, but most have acknowledged that reimbursement agreements for tests with miscellaneous or unlisted codes have to be secured payor by payor, which is a costly and time-consuming process.

Follow this link:
AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement?

Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities – Emphasis on NGS and Its Emerging …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/aa887c/molecular_diagnost) has announced the addition of the "Molecular Diagnostics: Market Segmentation and Opportunities - 4th Edition" report to their offering.

Molecular diagnostics (MDx) are a class of in vitro diagnostic (IVD) tests that identify nucleic acids, such as DNA. MDx tests may identify nucleic acids that are the genetic material of foreign organisms (e.g., HIV genotyping, MRSA screening) or the genetic markers of an individual patient (e.g., Her-2 overexpression for breast cancer, Factor V Leiden for coagulation). MDx tests continue to be the fastest growing segment within the IVD space, driven by high sensitivity, fast turnaround time, easy workflow and relatively low-cost compared to other techniques, such as culture-based or immune-based tests.

MDx involves platforms and assays that leverage multiple technologies to identify genetic variations. Technologies utilized include; PCR (e.g., HBV qualitative screening; Roche) qPCR (e.g., MRSA screening; Cepheid), TMA (CT/GC screening; Gen-Probe), FISH (PathVysion Her-2; Abbott), capillary electrophoresis (CE) sequencing (e.g., BRAC 1/2 testing; Myriad Genetics), next generation sequencing (Trisomy21 test; Sequenom), microarrays (Amplichip, Roche) and a host of other methods (e.g., pyrosequencing, bDNA, hybrid capture, hybridization beads, kPCR, electrochemical detection).

Analysis from this report indicates that the -$5.9B MDx market (2011E) is expected to grow at >15% p.a. over the next 4 years, reaching $10.9B by 2015. MDx growth is expected to continue to be driven by increased incidence of chronic diseases due to an aging population, increased availability of various tests, and the further adoption of Pharmacogenomics / personalized medicine.

This report reviews the market size, growth, segments and trends of the MDx industry from 2007 through 2015. The market is segmented to provide insights on specific growth opportunities by therapeutic area (infectious diseases, oncology, HPV, others), technology (PCR, qPCR, TMA, hybrid capture, CE Sequencing, NGS, FISH, other), analytes tested (low and high plex level), test rationale (predisposition, screening, diagnosis, therapy selection, monitoring), test location (reference labs, academic hospitals, blood banks, other) and geography (U.S., Europe, Japan, rest of the world). Growth and growth drivers for each segment are quantified and reviewed.

Major competitors shaping the industry include BioPharma (e.g., Abbott, Roche), IVD/MDx pure-play companies (e.g., Myriad Genetics, Cepheid, Gen-probe) or research tool companies (e.g., Illumina, Life Technologies). Major competitors are reviewed along with their key platforms and underlying technologies.

MDx is a highly regulated space. IVD instruments/assays are treated as medical devices and often require 510(k)/IVD clearance to gain full adoption in the marketplace. We briefly review the various level of clearance for MDx tests.

Finally, this report explores opportunities and challenges in the MDx industry. In this fourth edition, we place an emphasis on NGS and its emerging adoption in clinical settings, as well as other emerging technologies (e.g., dPCR, CGH).

Key Topics Covered:

Read more from the original source:
Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities - Emphasis on NGS and Its Emerging ...

Transgenomic's Q4 Revenues Increase 69 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) Transgenomic today reported 69 percent revenue growth year over year for the fourth quarter.

For the period ended Dec. 31, 2011, the Omaha, Neb.-based firm posted $8.6 million in revenues, up from $5.1 million a year ago. The Clinical Labs business recorded $4.6 million in revenue, Diagnostic Tools saw $3.5 million in revenues, and Pharmacogenomics had $500,000 in revenues.

Its R&D costs increased 60 percent to $568,000 from $354,000 a year ago, and SG&A costs rose 48 percent to $4.9 million from $3.3 million.

A net loss of $767,000, or $.02 per share, in Q4 2010 was turned into a profit of $263,000, or break-even on a per-share basis, in Q4 2011.

For full-year 2011, Transgenomic saw revenues climb to $32 million, up 60 percent year over year from $20 million in 2010. Clinical Labs revenue came in at $16 million, Diagnostic tools had $13.7 million, and Pharmacogenomics had $2.3 million.

Transgenomic decreased R&D spending 4 percent year over year to $2.2 million from $2.3 million but increased SG&A spending 76 percent to $19.2 million from $10.9 million.

The company had a net loss of $9.8 million, or $.22 per share, compared to a net loss of $3.1 million, or $.06 per share, in 2010. Transgenomic attributed the increase in net loss to an interest expense of $1 million and non-cash charges for preferred-stock valuation of $6.1 million, as well as amortization related to acquired intangibles and stock option expenses.

The firm ended 2011 with $4.9 million in cash and cash equivalents.

In a statement, Transgenomic President and CEO Craig Tuttle said that the year-over-year growth in 2011 reflected improvement in the firm's clinical reference lab and pharmacogenomics lab businesses.

View original post here:
Transgenomic's Q4 Revenues Increase 69 Percent

Transgenomic Reports Fiscal Year 2011 Financial Results

OMAHA, Neb.--(BUSINESS WIRE)--

Transgenomic, Inc. (OTCBB: TBIO.OB - News) today reported financial results for the year ended December 31, 2011 and provided a business update.

Transgenomic enjoyed a landmark year in 2011, with revenue growth quarter-over-quarter and year-over-year as well as an attention to expense management translating into positive modified EBITDA for both the fourth quarter and full year 2011 periods, said Craig Tuttle, President and Chief Executive Officer. Our year-over-year top line increase of 59%, to $32 million in revenue for 2011, reflects growth in both our clinical reference labs and pharmacogenomics lab businesses. These encouraging top- and bottom-line results were achieved without compromising our investment in the development of groundbreaking new technologies. Supporting our strategic direction, and adding substantially to shareholder equity, was a $22 million private placement financing executed last month with a number of top-tier life sciences investors.

Mr. Tuttle continued: 2012 promises to be yet another important year for growth and value creation, as we look to build momentum behind our recently launched products, including our proprietary clopidogrel response panel, expand on our growing position as a key partner in cancer research and develop the markets where our products and services are available. As always, we will continue to focus on the successful integration of new products and technologies and expansion into new markets, all while managing toward the bottom line.

Recent Corporate and Business Events

Fourth Quarter and Fiscal Year Financial Results

Total revenue for the fourth quarter 2011 was $8.6 million, an increase of 68 percent compared with $5.1 million for the same period of 2010. Revenues for the fourth quarter of 2011 included $4.6 million in sales related to the Clinical Labs business, $0.5 million in revenue related to the Pharmacogenomics Services Unit (Pharma which supports Clinical Trials) and $3.5 million in revenue related to the Diagnostic Tools unit.

For the year ended December 31, 2011, revenues were $32.0 million, an increase of 59 percent compared with $20.0 million for the same period of 2010. This included $16.0 million in net sales related to the Clinical Labs, $2.3 million in Pharma revenues and $13.7 million in revenues related to the Diagnostic Tools unit.

Gross profit was $5.3 million, or 62 percent of net sales during the fourth quarter of 2011, compared with gross profit of $2.4 million, or 47 percent of net sales during the comparable period of 2010. Gross profit was $18.4 million, or 58 percent of net sales for 2011, compared with gross profit of $9.8 million, or 49 percent of net sales for 2010. The improvement in gross margin for the fourth quarter and full year is attributable to improvement in our Lab Services and Pharmacogenomic margins. The improvement in our Lab Services is due to the revenue from the FAMILION acquisition and successful consolidation of operations and reduction of overhead costs. Our Pharmacogenomics margins have improved due to the revenue increase quarter-over-quarter and year-over-year as the costs in that segment are relatively fixed.

Operating expenses were $5.4 million during the fourth quarter of 2011, compared to $3.7 million during the same period of 2010. Operating expenses increased primarily due to the acquisition of the FAMILION business, including non-cash charges totaling $0.3 million related to the amortization of the acquired intangibles. Operating expenses for the year ended December 31, 2011 were $21.4 million, compared with $13.4 million for 2010. Operating expenses increased primarily due to the acquisition of the FAMILION business, including non-cash charges for amortization related to the acquired intangibles of $1.2 million. We also recorded non-cash charges for stock option expenses of $1.0 million and bad debt expense of $1.7 million.

Excerpt from:
Transgenomic Reports Fiscal Year 2011 Financial Results

GM a “cautionary tale” for nanotechnology

Hearts and minds need to be won in the battle to commercialise nanotechnology, if it is to avoid going the same way as GM food, according to a new study.

Public acceptance of such new technology being introduced to the food and agriculture sector is a major challenge for stakeholders, according to the study published in called Implications of nanotechnology growth in food and agriculture in OECD countries.

The report, by Guillaume Grure of the International Food Policy Research Institute, USA,comes as a FoodNavigator.com poll found that 73% of readers believe the European Commission should heed calls to ban GM crops .

Published in the April issue of Food Policy, the study identifies three main policy challenges; funding and investment, risk governance, and public acceptance.

Public acceptance is seen as critical and researchers have emphasized the importance of delivering the right message from a trusted authority.

However, the author states: The GM food rejection in OECD countries provides an illustration of what needs to be avoided. At the same time, despite all warning, there are signs that nano food products may face the exact same consumer rejection as GM food.

Similarly he suggests that industry needs to proactively communicate transparently on the use of nanotechnology in food.

Nano

Nanotechnology-enabled products were defined as those derived or issued from materials at scales measuring less than 100 nm in at least one dimension.

They are being developed and commercialized for improved processing and nutrition, among others, but its rapid emergence has raised concerns.

Go here to read the rest:
GM a “cautionary tale” for nanotechnology

Montreal landmark wins Lego contest, but not immortality

Home : Canada : Montreal landmark wins Lego contest, but not immortality

The Canadian Press

Date: Wednesday Mar. 7, 2012 1:21 PM ET

MONTREAL A quirky Montreal landmark has won an international competition among Lego enthusiasts -- but the thrill of victory has been tempered by the sting of rejection.

The Habitat 67 housing complex won an Internet vote, beating out iconic structures like Paris' Eiffel Tower, Rome's Coliseum and the U.S. Capitol Building in Washington D.C.

The Lego company, without making any promises, had said it would consider creating a toy set inspired by the winning entry.

But the company has announced there won't be a toy version of Montreal's Habitat 67, at least not for now. Lego says it will consider such a project in the future.

Designed by Israeli-Canadian architect Moshe Safdie, Habitat 67 is a unique project built for the city's world fair in 1967. It's an integrated series of blocks of housing units near downtown Montreal's waterfront. It was declared a historic site by Quebec in 2009.

The company says it can't commit to building something just because it won a contest.

"It takes more than popularity to make the grade as a Lego Architecture icon," the company noted on its website.

Originally posted here:
Montreal landmark wins Lego contest, but not immortality

Montreal landmark wins Lego contest, but not Lego immortality

MONTREAL - A quirky Montreal landmark has won an international competition among Lego enthusiasts but the thrill of victory has been tempered by the sting of rejection.

The Habitat 67 housing complex won an Internet vote, beating out iconic structures like Paris' Eiffel Tower, Rome's Coliseum and the U.S. Capitol Building in Washington D.C.

The Lego company had, without making any promises, had said it would consider creating a toy set inspired by the winning entry.

But the company has announced there won't be a toy version of Montreal's Habitat 67, at least not for now. Lego says it will consider such a project in the future.

Designed by Israeli-Canadian architect Moshe Safdie, Habitat 67 is a unique project built for the city's world fair in 1967. It's an integrated series of blocks of housing units near downtown Montreal's waterfront. It was declared a historic site by Quebec in 2009.

The company says it can't commit to building something just because it won a contest.

"It takes more than popularity to make the grade as a Lego Architecture icon," the company noted on its website.

The company has moved on to its next architectural contest. Ten new choices have appeared on Lego's website including San Francisco's Golden Gate Bridge, the Leaning Tower of Pisa and Saint-Basil's Cathedral in Red Square in Moscow.

On the web: http://architecture.lego.com/en-us/inspire-us/

See more here:
Montreal landmark wins Lego contest, but not Lego immortality